GALD.Y Stock Overview

Operates as a dermatology company worldwide. More details

GALD.Y fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 49.1% below our estimate of its fair value

Earnings are forecast to grow 36.37% per year

Revenue grew by 8.8% over the past year

Risk Analysis

No risks detected for GALD.Y from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Galderma Group AG Competitors

Teva Pharmaceutical Industries

NYSE:TEVA

US$24.1b

Royalty Pharma

NasdaqGS:RPRX

US$15.2b

Viatris

NasdaqGS:VTRS

US$14.7b

Zoetis

NYSE:ZTS

US$73.7b

Price History & Performance

Summary of share price highs, lows and changes for Galderma Group
Historical stock prices
Current Share Price	CHF 21.98
52 Week High	CHF 22.80
52 Week Low	CHF 15.51
Beta	0
1 Month Change	9.14%
3 Month Change	21.10%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	34.11%

Recent updates

Shareholder Returns

	GALD.Y	US Pharmaceuticals	US Market
7D	-1.4%	-0.6%	-0.2%
1Y	n/a	3.0%	25.8%

Return vs Industry: Insufficient data to determine how GALD.Y performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GALD.Y performed against the US Market.

Price Volatility

Is GALD.Y's price volatile compared to industry and market?
GALD.Y volatility
GALD.Y Average Weekly Movement	6.2%
Pharmaceuticals Industry Average Movement	10.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: GALD.Y has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine GALD.Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	6,545	Flemming Ornskov	www.galderma.com

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology.

Galderma Group AG Fundamentals Summary

How do Galderma Group's earnings and revenue compare to its market cap?
GALD.Y fundamental statistics
Market cap	US$26.66b
Earnings (TTM)	-US$14.20m
Revenue (TTM)	US$4.32b

6.2x

P/S Ratio

-1,877x

P/E Ratio

Is GALD.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GALD.Y income statement (TTM)
Revenue	US$4.32b
Cost of Revenue	US$1.31b
Gross Profit	US$3.00b
Other Expenses	US$3.02b
Earnings	-US$14.20m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Mar 06, 2025

Earnings per share (EPS)	-0.06
Gross Margin	69.54%
Net Profit Margin	-0.33%
Debt/Equity Ratio	37.1%

How did GALD.Y perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 05:18
End of Day Share Price	2025/01/02 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Galderma Group AG is covered by 12 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bethan Davies	Berenberg
Richard Parkes	BNP Paribas Exane
Joffrey Meller	BofA Global Research